Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili™, a Biosimilar to Eylea® (Aflibercept)

BENGALURU, India & BRIDGEWATER, N.J.-- (BUSINESS WIRE)--Jul 9, 2026-- ...
Seeking Alpha

Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis

BRIDGEWATER, N.J., and BENGALURU, India, March 7, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: ...
Reuters

India's Biocon developing its own version of Wegovy, clinical trial likely next year

HYDERABAD, April 18 (Reuters) - Indian drugmaker Biocon (BION.NS), opens new tab, looking to grab a piece of the exploding weight-loss drug market as early as possible, is developing its own version ...
FiercePharma

Biocon denies allegations it bribed regulator to waive diabetes drug's pivotal trial

New insulin treatments for diabetes are hitting the market fast and furious these days. Biocon Biologics’ effort to move its insulin through the approval process in India, however, has landed the ...